Abingworth, of London, named John Heard general counsel.

Acuity Pharmaceuticals Inc., of Philadelphia, named Denis O'Shaughnessy senior vice president of clinical development.

Advancis Pharmaceutical Corp., of Germantown, Md., promoted Robert Low to vice president of finance and chief financial officer, and Robert Bannon to vice president of investor relations and corporate communications.

Adventrx Pharmaceuticals Inc., of San Diego, appointed Alexander Denner to its board.

Affymax Inc., of Palo Alto, Calif., named Grace Shin vice president of legal affairs and corporate counsel.

Akesis Pharmaceuticals Inc., of San Diego, named Jay Lichter president and CEO.

Amylin Pharmaceuticals Inc., of San Diego, named Joe Young senior vice president of marketing.

Archemix Corp., of Cambridge, Mass., named James Gilbert chief medical officer and senior vice president of clinical and regulatory affairs.

Athenagen Inc., of South San Francisco, named John Anthony Hey vice president of nonclinical development and Carl Grove vice president of development operations.

Bioenvision Inc., of New York, named MaryJane Rafii vice president of regulatory affairs.

Cabrellis Pharmaceuticals Corp., of San Diego, named Tracy Lawhon vice president of regulatory affairs and development operations.

CardioVascular BioTherapeutics Inc., of Las Vegas, named Grant Gordon vice chairman.

Cellectis SA, of Romainville, France, named Marc Le Bozec chief financial officer.

Cleveland BioLabs Inc., of Cleveland, named John Gordon director of clinical operations.

Cyclacel Pharmaceuticals Inc., of Short Hills, N.J., named John Womelsdorf vice president of business development.

enGene Inc., of Vancouver, British Columbia, appointed Christopher Rhodes and Imre Kovesdi scientific advisers.

Genentech Inc., of South San Francisco, named Leonard Kanavy vice president of commercial operations and Anthony Hurley vice president of fill/finish manufacturing.

Ilypsa Inc., of Santa Clara, Calif., named William Waddill chief financial officer.

Immtech Pharmaceuticals Inc., of New York, appointed Donald Sinex to its board.

Innovive Pharmaceuticals Inc., of New York, named J. Gregory Jester vice president and chief financial officer.

Insmed Inc., of Richmond, Va., named Doug Farrar vice president of Insmed Therapeutic Proteins.

IntegraGen SA, of Paris, named Emmanuel Martin director of sales and marketing for its new genetic research service business unit.

Invitrogen Corp., of Carlsbad, Calif., promoted Bernd Brust to the newly created position of senior vice president of sales for Europe and the Americas.